GMJ Medicine
eISSN : 2626-3041
Embase
Biosis Previews
description
Volume 3, Issue 1 (2024)
GMJM 2024, 3(1): 25-29 |
Back to browse issues page
History
Received: 2023/06/25 | Accepted: 2023/12/7 | Published: 2024/01/20
Received: 2023/06/25 | Accepted: 2023/12/7 | Published: 2024/01/20
How to cite this article
Yousefi S, Nemati Karimooy F, Miyanbandi T, Esmaeilpour F. Effect of Dietary Supplementing with Resveratrol on the Antioxidant Status of Hypercholestrolemic Rats. GMJM 2024; 3 (1) :25-29
URL: http://gmedicine.de/article-2-246-en.html
URL: http://gmedicine.de/article-2-246-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Biochemistry, Faculty of Medicine, Semnan University of Medical Science, Semnan, Iran
2- Medical School, Mashhad University of Medical Sciences, Mashhad, Iran
3- School of Nursing & Midwifery, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran
4- Georgian Center for Neuroscience Research, International Center for Intelligent Research, Tbilisi, Georgia
2- Medical School, Mashhad University of Medical Sciences, Mashhad, Iran
3- School of Nursing & Midwifery, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran
4- Georgian Center for Neuroscience Research, International Center for Intelligent Research, Tbilisi, Georgia
Abstract (499 Views)
Aims: Natural agents have been used for protection against damages. This study was conducted to evaluate the effects of dietary supplementing of resveratrol improves on antioxidant status improvement in hypercholestrolemic rats.
Materials & Methods: Rats were divided into 6 groups including rats fed with basal diet (Control group), basal diet containing resveratrol 2.5mg/kg (2.5 RES), basal diet containing 5.0mg/kg of resveratrol (5.0 RES), basal diet containing 1% cholesterol + 0.5% cholic acid (Control HC), basal diet containing 2.5mg/kg of resveratrol and 1% cholesterol + 0.5% cholic acid (2.5 RES-HC), basal diet containing resveratrol 5.0mg/kg and 1% cholesterol + 0.5% cholic acid (5.0 RES-HC). The plasma levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), malondialdehyde (MDA), and low density lipoprotein (LDL) and expression levels of glutathione peroxidase (GPx), glutathione reductase (GR), paraoxonase-1 and sulfiredoxin-1 were assessed.
Findings: The plasma concentrations of cholesterol, triglycerides, LDL-C and malondialdehyde were significantly higher and level of HDL was significantly lower in hypercholesterolemic rats, but dietary supplementation resveratrol significantly improved them (p<0.05). Hypercholesterolemic rats showed a decrease in GPx and GR and an increase in paraoxonase-1 and sulfiredoxin-1 compared to the healthy control (p<0.05), but applying resveratrol improved the adverse effects of hypercholesterolemia on mentioned parameters (p<0.05).
Conclusion: Resveratrol can be used for treatment of patients with hypercholesterolemia.
Materials & Methods: Rats were divided into 6 groups including rats fed with basal diet (Control group), basal diet containing resveratrol 2.5mg/kg (2.5 RES), basal diet containing 5.0mg/kg of resveratrol (5.0 RES), basal diet containing 1% cholesterol + 0.5% cholic acid (Control HC), basal diet containing 2.5mg/kg of resveratrol and 1% cholesterol + 0.5% cholic acid (2.5 RES-HC), basal diet containing resveratrol 5.0mg/kg and 1% cholesterol + 0.5% cholic acid (5.0 RES-HC). The plasma levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), malondialdehyde (MDA), and low density lipoprotein (LDL) and expression levels of glutathione peroxidase (GPx), glutathione reductase (GR), paraoxonase-1 and sulfiredoxin-1 were assessed.
Findings: The plasma concentrations of cholesterol, triglycerides, LDL-C and malondialdehyde were significantly higher and level of HDL was significantly lower in hypercholesterolemic rats, but dietary supplementation resveratrol significantly improved them (p<0.05). Hypercholesterolemic rats showed a decrease in GPx and GR and an increase in paraoxonase-1 and sulfiredoxin-1 compared to the healthy control (p<0.05), but applying resveratrol improved the adverse effects of hypercholesterolemia on mentioned parameters (p<0.05).
Conclusion: Resveratrol can be used for treatment of patients with hypercholesterolemia.
Keywords:
| | Full-Text (HTML) (18 Views)
References
1. Otunola GA, Oloyede OB, Oladiji AT, Afolayan AA. Effects of diet-induced hypercholesterolemia on the lipid profile and some enzyme activities in female Wistar rats. Afr J Biochem Res. 2010;4(6):149-54. [Link]
2. Matos SL, Paula H, Pedrosa ML, Santos RC, Oliveira EL, Chianca Jr DA, et al. Dietary models for inducing hypercholesterolemia in rats. Braz Arch Biol Technol. 2005;48(2):203-9. [Link] [DOI:10.1590/S1516-89132005000200006]
3. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112-7. [Link] [DOI:10.7326/0003-4819-132-2-200001180-00004]
4. Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, et al. Coffee reduces liver damage in a rat model of steatohepatitis: The underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 2010;52(5):1652-61. [Link] [DOI:10.1002/hep.23902]
5. Araya J, Rodrigo R, Pettinelli P, Araya AV, Poniachik J, Videla LA. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity (Silver Spring). 2010;18(7):1460-3. [Link] [DOI:10.1038/oby.2009.379]
6. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med. 2006;12(12):555-8. [Link] [DOI:10.1016/j.molmed.2006.10.001]
7. Sonta T, Inoguchi T, Tsubouchi H, Sekiguchi N, Kobayashi K, Matsumoto S, et al. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic Biol Med. 2004;37(1):115-23. [Link] [DOI:10.1016/j.freeradbiomed.2004.04.001]
8. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752-61. [Link] [DOI:10.1172/JCI21625]
9. Faienza MF, Francavilla R, Goffredo R, Ventura A, Marzano F, Panzarino G, et al. Oxidative stress in obesity and metabolic syndrome in children and adolescents. Horm Res Paediatr. 2012;78(3):158-64. [Link] [DOI:10.1159/000342642]
10. Park S, Kim M, Paik JK, Jang YJ, Lee SH, Lee JH. Oxidative stress is associated with C-reactive protein in non-diabetic postmenopausal women, independent of obesity and insulin resistance. Clin Endocrinol. 2012;79(1):65-70. [Link] [DOI:10.1111/j.1365-2265.2012.04512.x]
11. Mishra KP. Cell membrane oxidative damage induced by gammaradiation and apoptotic sensitivity. J Environ Pathol Toxicol Oncol. 2004;23(1):61-6. [Link] [DOI:10.1615/JEnvPathToxOncol.v23.i1.60]
12. Bravo E, Palleschi S, Aspichueta P, Buque X, Rossi B, Cano A, et al. High fat diet-induced non alcoholic fatty liver disease in rats is associated with hyperhomocysteinemia caused by down regulation of the transsulphuration pathway. Lipids Health Dis. 2011;10:60. [Link] [DOI:10.1186/1476-511X-10-60]
13. Koc A, Duru M, Ciralik H, Akcan R, Sogut S. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol Cell Biochem. 2005;278(1-2):79-84. [Link] [DOI:10.1007/s11010-005-6630-z]
14. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: A review. Ann Bot. 2003;91 Spec No(2):179-94. [Link] [DOI:10.1093/aob/mcf118]
15. Yagmurca M, Bas O, Mollaoglu H, Sahin O, Nacar A, Karaman O, et al. Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res. 2007;38(4):380-5. [Link] [DOI:10.1016/j.arcmed.2007.01.007]
16. Sayed Ahmed MM, Aleisa AM, Al Rejaie SS, Al Yahya AA, Al Shabanah OA, Hafez MM, et al. Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling. Oxid Med Cell Longev. 2010;3(4):254-61. [Link] [DOI:10.4161/oxim.3.4.12714]
17. Senti M, Tomas M, Fito M, Weinbrenner T, Covas MI, Sala J, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab. 2003;88(11):5422-6. [Link] [DOI:10.1210/jc.2003-030648]
18. Peltoniemi MJ, Rytila PH, Harju TH, Soini YM, Salmenkivi KM, Ruddock LW, et al. Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease. Respir Res. 2006;7(1):133. [Link] [DOI:10.1186/1465-9921-7-133]
19. Lu W, Chen Z, Zhang H, Wang Y, Luo Y, Huang P. ZNF143 transcription factor mediates cell survival through upregulation of the GPX1 activity in the mitochondrial respiratory dysfunction. Cell Death Dis. 2012;3:e422. [Link] [DOI:10.1038/cddis.2012.156]
20. Sharma R, Sharma NK, Thungapathra M. Resveratrol regulates body weight in healthy and ovariectomized rats. Nutr Metab (Lond). 2017;14:30. [Link] [DOI:10.1186/s12986-017-0183-5]
21. Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053-63. [Link] [DOI:10.1016/j.bcp.2008.11.027]
22. Al-Rejaie SS, Aleisa AM, Sayed-Ahmed MM, AL-Shabanah OA, Abuohashish HM, Ahmed MM, et al. Protective effect of rutin on the antioxidant genes expression in hypercholestrolemic male Westar rat. BMC Complement Altern Med. 2013;13:136. [Link] [DOI:10.1186/1472-6882-13-136]
23. Madsen AN, Hansen G, Paulsen SJ, Lykkegaard K, Tang Christensen M, Hansen HS, et al. Long-term characterization of the diet-induced obese and diet-resistant rat model: A polygenetic rat model mimicking the human obesity syndrome. J Endocrinol. 2010;206(3):287-96. [Link] [DOI:10.1677/JOE-10-0004]
24. Tsimikas S, Miller YI. Oxidative modification of lipoproteins: Mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des. 2011;17(1):27-37. [Link] [DOI:10.2174/138161211795049831]
25. Noeman SA, Hamooda HE, Baalash AA. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetol Metab Syndr. 2011;3(1):17. [Link] [DOI:10.1186/1758-5996-3-17]
26. Bloomgarden ZT. Dyslipidemia and the metabolic syndrome. Diabetes Care 2004;27(12):3009-16. [Link] [DOI:10.2337/diacare.27.12.3009]
27. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic. 1992;43:49-52. [Link] [DOI:10.5344/ajev.1992.43.1.49]
28. Afaq F, Adhami VM, Ahmad N. Prevention of short-term ultraviolet B radiationmediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol.2003;186(1):28-37. [Link] [DOI:10.1016/S0041-008X(02)00014-5]
29. Azorín Ortuño M, Yañéz Gascón MJ, Pallarés FG, Rivera J, González Sarrías A, Larrosa M, et al. A dietary resveratrol-rich grape extract prevents the developing of atherosclerotic lesions in the aorta of pigs fed an atherogenic diet. J Agric Food Chem. 2012;60(22):5609-20. [Link] [DOI:10.1021/jf301154q]
30. Tappel AL. Glutathione peroxidase and hydroperoxides. Methods Enzymol. 1978;52:506-13. [Link] [DOI:10.1016/S0076-6879(78)52055-7]
31. Pradeep K, Mohan CV, Gobianand K, Karthikeyan S. Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur J Pharmacol. 2007;560(2-3):110-6. [Link] [DOI:10.1016/j.ejphar.2006.12.023]
32. Rodrigo L, Gil F, Hernandez AF, Marina A, Vazquez J, Pla A. Purification and characterization of paraoxon hydrolase from rat liver. Biochem J. 1997;321(Pt 3):595-601. [Link] [DOI:10.1042/bj3210595]
33. Ferre N, Marsillach J, Camps J, Mackness B, Mackness M, Riu F, et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol. 2006;45(1):51-9. [Link] [DOI:10.1016/j.jhep.2005.12.018]
34. Rhee SG, Jeong W, Chang TS, Woo HA. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: Its discovery, mechanism of action, and biological significance. Kidney Int Suppl. 2007;(106):S3-8. [Link] [DOI:10.1038/sj.ki.5002380]